North America Active Implantable Medical Devices Market Size & Outlook, 2025-2033

North America Active Implantable Medical Devices Market Size

The North America active implantable medical devices market size was valued at USD 9.49 billion in 2024 and is projected to reach from USD 10.11 billion in 2025 to USD 16.73 billion by 2033, growing at a CAGR of 6.5% during the forecast period (2025–2033).

Technological advancements in AIMDs, the rising prevalence of chronic diseases, and the presence of a robust healthcare infrastructure drive the region's market. Furthermore, the increasing demand for advanced cardiac care devices and neuromodulation systems also supports the growth of this market.

To get more insights about this report Download Free Sample Report

North America Active Implantable Medical Devices Market Growth Factor

Technological Advancements in Aimds

One of the primary drivers of the North American AIMDs market is the continuous technological innovation in medical devices. These advancements have led to development of compact, energy-efficient devices with improved efficacy and safety profiles. For example, implantable cardioverter defibrillators (ICDs), a leading subsegment, have seen innovations such as wireless monitoring capabilities, which allow real-time data sharing with healthcare providers.

Additionally, according to the American Heart Association (AHA) 2024 report, cardiovascular diseases account for 37% of deaths in North America. This prevalence has driven demand for cardiac devices such as pacemakers and ICDs. Minimally invasive surgical device implantation techniques reduce recovery times and boost adoption rates. Innovations like biocompatible materials and rechargeable batteries enhance patient comfort and product durability, creating significant market growth potential.

Restraining Factor

High Costs of Devices and Procedures

The high costs associated with active implantable medical devices remain a significant challenge.

• For instance, implantable neurostimulators and ICDs are priced between USD 10,000 and USD 25,000, making them inaccessible for many patients without comprehensive insurance coverage.

Additionally, the implantation procedures are costly, with average hospital charges exceeding USD 50,000 in the U.S., according to a 2025 report by the Centers for Medicare & Medicaid Services (CMS).

Furthermore, the financial burden for healthcare providers is compounded by stringent regulatory approval processes and post-market surveillance requirements. Moreover, the disparity in reimbursement policies across North America hinders market penetration, especially in rural areas. This restraint disproportionately affects small and medium-sized healthcare facilities that need more resources to invest in cutting-edge technologies.

Market Opportunity

Growing Applications of Neuromodulation Devices

The expanding application of neuromodulation devices presents a lucrative opportunity in the North American AIMDs market. These devices are increasingly used to manage conditions such as chronic pain, Parkinson’s disease, and epilepsy. The adoption of spinal cord stimulators (SCS) is particularly noteworthy, as they offer effective pain relief without reliance on opioids a critical advantage amid the region's ongoing opioid crisis.

• In addition, according to the North American Neuromodulation Society (NANS), the demand for neuromodulation devices is expected to grow at 8.3% CAGR by 2032, fueled by rising neurological disorder cases. Additionally, advancements in closed-loop technology enable real-time adjustments based on patient responses, improving therapeutic outcomes. These innovations are opening doors to broader acceptance across various demographics, including aging populations and veterans suffering from chronic pain.

Country Insights

The market is characterized by a strong healthcare infrastructure, high disposable income, and early adoption of advanced medical technologies. The growth trajectory varies across countries based on healthcare spending, disease prevalence, and regulatory frameworks.

• The U.S. accounts for the largest share of the North American AIMDs market. The CDC reported in 2024 that nearly 6 million Americans suffer from heart failure, driving demand for pacemakers and ICDs. Companies like Abbott Laboratories and Boston Scientific lead the market with innovations such as Bluetooth-enabled pacemakers. The U.S. government's focus on expanding healthcare access through programs like Medicare Advantage further supports growth.
• Canada's AIMDs market is driven by its universal healthcare system, which covers a significant portion of device implantation costs. The rise in neurological disorders, reported by the Canadian Neurological Sciences Federation (CNSF), has spurred demand for neurostimulators. Additionally, government grants for medical research and device development support the market's expansion.
• Mexico is emerging as a growing market, driven by increasing healthcare awareness and medical tourism. Affordable procedures attract international patients, particularly for cardiac implants. The Mexican Ministry of Health reported a 12% annual increase in pacemaker implantation in 2024.
• Puerto Rico, with its growing healthcare infrastructure and access to advanced medical devices, contributes to regional growth. Investments in healthcare facilities and research by multinational companies strengthen its market position.
• Cuba's healthcare system emphasizes preventive care, but collaborations with foreign manufacturers have introduced AIMDs to manage severe cases. Ongoing partnerships between Cuban health authorities and global players like Medtronic are expected to boost growth.

Product Insights

Implantable Cardioverter Defibrillators dominate the product segment and is expected to grow at a CAGR of 7.2% over the forecast period. These devices are integral in preventing sudden cardiac deaths, especially among patients with arrhythmias. The development of subcutaneous ICDs (S-ICDs) further enhances adoption, offering a less invasive alternative to traditional ICDs. Key manufacturers like Medtronic and Boston Scientific are driving innovation in this segment.

End User Insights

Hospitals dominates the end-user segment and is expected to grow at a CAGR of 6.6% during the forecast period. Hospitals remain the primary point of care for AIMD implantation due to their advanced infrastructure and skilled personnel. Increasing investments in robotic-assisted surgeries further bolster this segment.

List of key players in North America Active Implantable Medical Devices Market

1. Medtronic PLC
2. Abbott Laboratories
3. Boston Scientific Corporation
4. Livanova PLC
5. Nurotron Biotechnology Co. Ltd.
6. Biotronik Se & Co., Kg
7. William Demant Holding A/S
8. Cochlear Limited
9. Sonova Holding AG

To get more findings about this report Download Market Share

Analyst’s Perspective

As per our analyst, the North America active implantable medical devices market is poised for rapid expansion in the coming years. This growth is primarily driven by advancements in AIMD technology, the rising prevalence of chronic diseases, and increasing healthcare investments across North America. The region's cardiac and neurological device innovation leadership positions it at the forefront of global trends.

Despite challenges like high costs, strategic initiatives such as improved reimbursement policies and investments in outpatient care facilities are expected to mitigate barriers. Additionally, adopting AI and wireless technologies in AIMDs will revolutionize the market, enabling better patient monitoring and outcomes. Companies investing in R&D to develop next-generation devices will likely capture significant market share, ensuring sustained growth through 2032.